An NCI-designated Comprehensive Cancer Center
Maung Htut

Maung Myo Htut, M.D.

Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation; Hematologist - Oncologist
Research Focus
  • Myeloma
There’s a real need for additional therapies for myeloma.”
 
Myo Htut, M.D., is determined to find more effective treatments for multiple myeloma, a rare blood cancer which strikes about 30,000 Americans each year. He believes the body's own immune system may hold the key. He's especially excited about the potential of CAR T cells – immune cells taken from the patient, re-engineered to destroy cancer, then re-introduced.
 
“It’s like we’re taking infantry soldiers and training them to be Navy SEALs whose only job is to find and kill these cancer cells,” he says.
 
A native of Myanmar, Dr. Htut received his medical degree at Yangon's Institute of Medicine. After interning at Yangon General Hospital he completed his residency at Harbor Hospital, Baltimore, as well as fellowships at University of Colorado and here at City of Hope.
 
Dr. Htut is conducting multiple clinical trials examining immunotherapy options for myeloma. Rounding out a decade at City of Hope, Dr. Htut says it is the “best place to take care of patients as well as doing research.”
Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Transplant. 2017 Oct 24. pii: S1083-8791(17)30793-0. DOI: 10.1016/j.bbmt.2017.10.024. [Epub ahead of print]. 

Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL.A phase !dose-escalation study on filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15;122(21):3327-333.5. DOI: 10.1002/cncr.30174. PMID: 27433944. 
 
Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, HtutM, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-hodgkin lymphoma. Haematologica. 2015 Mar; 100(3):357-62. DOI: 10.3324/haematol.2014.117473 PMID:25596263. 

Twice-weekly Oral Ixazomib Citrate (MLN9708), an Investigational Proteasome Inhibitor, in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data -ASH poster 2013. 

Deauna-Limayo D, Rajabi B, Qiu W, Htut, M, Swetenham J. Kaposi's Sacroma After Non-Myeloablative Hematopoietic Stem Cell Transplant: Response to Withdraw! of Immunosuppressant Therapy Correlated with Whole Blood Human Herpes Virus-8 RT-PCR levels. Leuk Lymphoma. 2013 Jan 24. [Epub ahead of print]. 

Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol. 2013 Jan;l60(2):199-206. DOI: 10.1111/bjh.12123. Epub 2112 Nov 15. 

Krishnan AY, Mei M, Sun CL, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant, 2012 Oct 13. Pii: Sl083-8791(12)00418-l doi: 10.1016/j.bbmt.2012.09.023 Epub 2012 Oct 13. 

 

Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.

In The News
An Expert's Voice
City of Hope News

City of Hope opens first multiple myeloma autologous CAR T cell therapy trial targeting CS1 protein on cancer cells